Research Article: Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy
Abstract:
Lung cancer is the leading cause of cancer-related death worldwide. Owing to advances in the molecular pathogenesis of the disease and the availability of new treatment options, the outcome of non-small cell lung cancer (NSCLC) has improved substantially. Antiangiogenic therapy, which can disrupt the blood supply to tumors and crosstalk with other antineoplastic treatments, have been proven with clinical benefits for patients with advanced NSCLC.,
Introduction:
Lung cancer is the leading cause of cancer-related death worldwide. Owing to advances in the molecular pathogenesis of the disease and the availability of new treatment options, the outcome of non-small cell lung cancer (NSCLC) has improved substantially. Antiangiogenic therapy, which can disrupt the blood supply to tumors and crosstalk with other antineoplastic treatments, have been proven with clinical benefits for patients with advanced NSCLC. ,
Read more